Results From A Phase 3 Study Of 1L Atezolizumab Vs Single-Agent Chemotherapy In Pts With Nsclc

Results from a phase 3 study of 1L atezolizumab vs single-agent chemotherapy in pts with NSCLC

IPSOS: 1L atezolizumab vs single-agent chemotherapy in patients with platinum-ineligible NSCLC

#ESMO22 Highlights on first-line atezolizumab in NSCLC not eligible for platinum: The IPSOS study

European Society for Medical Oncology (ESMO)

Dr Adwaita Gore | IPSOS Results from a Phase III Study of first line1L atezolizumab vs single agent

CRSF - Cancer Research and Statistic Foundation

Atezolizumab improves on single-agent chemo for NSCLC not eligible for platinum-containing regimen

Phase 3 trials of atezolizumab versus standard chemotherapy in PD-L1-selected NSCLC

EMJ

ESMO22 - LBA11 IPSOS - Results 1st-line atezolizumab vs single-agent CT in NSCLC not eligible f...

IMpower010: A Phase 3 study of atezolizumab vs best supportive care after adjuvant chemotherapy ...

#ESMO21 Highlights on patterns of relapse in NSCLC to atezolizumab vs BSC after adj CT: IMpower010

European Society for Medical Oncology (ESMO)

Dr. Melissa Johnson on Atezolizumab in Patients With NSCLC

Final OS results of IMvigor130: 1L atezolizumab +/- chemotherapy in metastatic urothelial carcinoma

New Phase 3 Data on PD-L1 Vs. Chemotherapy for First-Line NSCLC

IMpower010: OS results of atezolizumab vs best supportive care in resected NSCLC

Dr. Wakelee on BIRCH Trial for Atezolizumab in Patients With NSCLC

Subgroup analysis of OAK trial data supports use of atezolizumab in patients with NSCLC

CITYSCAPE: 1L tiragolumab + atezolizumab vs placebo + atezolizumab in PD-L1-selected NSCLC

Real-world study of atezolizumab vs. pembrolizumab for advanced/metastatic UC

Phase 3 IMvigor130 results: atezolizumab in untreated metastatic urothelial carcinoma

Atezolizumab for locally advanced or metastatic PD-L1-selected NSCLC

IMpower110: atezolizumab vs chemo in PD-L1–selected NSCLC